Potent anti-cancer agents
Despite advances in immuno-oncology, many solid tumors remain stubbornly difficult to treat. Aktis is developing a pipeline of multiple precision engineered targeting molecules to deliver the curative power of alpha radiotherapy to a range of cancers including breast, lung, colorectal, bladder, and liver cancers.
A pipeline of targeting molecules
Our programs are currently in preclinical development, rapidly advancing novel radiopharmaceuticals toward the clinic. We look forward to sharing more information as the programs advance.